
<!DOCTYPE html>

<html>
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta name="generator" content="Docutils 0.17.1: http://docutils.sourceforge.net/" />

    <title>2022 (lst) &#8212; Study of Guidance (Public domain)</title>
    
  <!-- Loaded before other Sphinx assets -->
  <link href="../_static/styles/theme.css?digest=1999514e3f237ded88cf" rel="stylesheet">
<link href="../_static/styles/pydata-sphinx-theme.css?digest=1999514e3f237ded88cf" rel="stylesheet">

    
  <link rel="stylesheet"
    href="../_static/vendor/fontawesome/5.13.0/css/all.min.css">
  <link rel="preload" as="font" type="font/woff2" crossorigin
    href="../_static/vendor/fontawesome/5.13.0/webfonts/fa-solid-900.woff2">
  <link rel="preload" as="font" type="font/woff2" crossorigin
    href="../_static/vendor/fontawesome/5.13.0/webfonts/fa-brands-400.woff2">

    <link rel="stylesheet" type="text/css" href="../_static/pygments.css" />
    <link rel="stylesheet" href="../_static/styles/sphinx-book-theme.css?digest=5115cc725059bd94278eecd172e13a965bf8f5a9" type="text/css" />
    <link rel="stylesheet" type="text/css" href="../_static/togglebutton.css" />
    <link rel="stylesheet" type="text/css" href="../_static/copybutton.css" />
    <link rel="stylesheet" type="text/css" href="../_static/mystnb.css" />
    <link rel="stylesheet" type="text/css" href="../_static/sphinx-thebe.css" />
    <link rel="stylesheet" type="text/css" href="../_static/myfile.css" />
    <link rel="stylesheet" type="text/css" href="../_static/.ipynb_checkpoints/myfile-checkpoint.css" />
    <link rel="stylesheet" type="text/css" href="../_static/design-style.b7bb847fb20b106c3d81b95245e65545.min.css" />
    
  <!-- Pre-loaded scripts that we'll load fully later -->
  <link rel="preload" as="script" href="../_static/scripts/pydata-sphinx-theme.js?digest=1999514e3f237ded88cf">

    <script data-url_root="../" id="documentation_options" src="../_static/documentation_options.js"></script>
    <script src="../_static/jquery.js"></script>
    <script src="../_static/underscore.js"></script>
    <script src="../_static/doctools.js"></script>
    <script src="../_static/clipboard.min.js"></script>
    <script src="../_static/copybutton.js"></script>
    <script src="../_static/scripts/sphinx-book-theme.js?digest=9c920249402e914e316237a7dbc6769907cce411"></script>
    <script>let toggleHintShow = 'Click to show';</script>
    <script>let toggleHintHide = 'Click to hide';</script>
    <script>let toggleOpenOnPrint = 'true';</script>
    <script src="../_static/togglebutton.js"></script>
    <script>var togglebuttonSelector = '.toggle, .admonition.dropdown, .tag_hide_input div.cell_input, .tag_hide-input div.cell_input, .tag_hide_output div.cell_output, .tag_hide-output div.cell_output, .tag_hide_cell.cell, .tag_hide-cell.cell';</script>
    <script src="../_static/design-tabs.js"></script>
    <script>const THEBE_JS_URL = "https://unpkg.com/thebe@0.8.2/lib/index.js"
const thebe_selector = ".thebe,.cell"
const thebe_selector_input = "pre"
const thebe_selector_output = ".output, .cell_output"
</script>
    <script async="async" src="../_static/sphinx-thebe.js"></script>
    <link rel="index" title="Index" href="../genindex.html" />
    <link rel="search" title="Search" href="../search.html" />
    <link rel="next" title="COVID-19" href="../ch002covid19/ch002_covid19.html" />
    <link rel="prev" title="About" href="../index.html" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta name="docsearch:language" content="None">
    

    <!-- Google Analytics -->
    
  </head>
  <body data-spy="scroll" data-target="#bd-toc-nav" data-offset="60">
<!-- Checkboxes to toggle the left sidebar -->
<input type="checkbox" class="sidebar-toggle" name="__navigation" id="__navigation" aria-label="Toggle navigation sidebar">
<label class="overlay overlay-navbar" for="__navigation">
    <div class="visually-hidden">Toggle navigation sidebar</div>
</label>
<!-- Checkboxes to toggle the in-page toc -->
<input type="checkbox" class="sidebar-toggle" name="__page-toc" id="__page-toc" aria-label="Toggle in-page Table of Contents">
<label class="overlay overlay-pagetoc" for="__page-toc">
    <div class="visually-hidden">Toggle in-page Table of Contents</div>
</label>
<!-- Headers at the top -->
<div class="announcement header-item noprint"></div>
<div class="header header-item noprint"></div>

    
    <div class="container-fluid" id="banner"></div>

    

    <div class="container-xl">
      <div class="row">
          
<!-- Sidebar -->
<div class="bd-sidebar noprint" id="site-navigation">
    <div class="bd-sidebar__content">
        <div class="bd-sidebar__top"><div class="navbar-brand-box">
    <a class="navbar-brand text-wrap" href="../index.html">
      
        <!-- `logo` is deprecated in Sphinx 4.0, so remove this when we stop supporting 3 -->
        
      
      
      <img src="../_static/logo.svg" class="logo" alt="logo">
      
      
      <h1 class="site-logo" id="site-title">Study of Guidance (Public domain)</h1>
      
    </a>
</div><form class="bd-search d-flex align-items-center" action="../search.html" method="get">
  <i class="icon fas fa-search"></i>
  <input type="search" class="form-control" name="q" id="search-input" placeholder="Search this book..." aria-label="Search this book..." autocomplete="off" >
</form><nav class="bd-links" id="bd-docs-nav" aria-label="Main">
    <div class="bd-toc-item active">
        
        <ul class="nav bd-sidenav bd-sidenav__home-link">
            <li class="toctree-l1">
                <a class="reference internal" href="../index.html">
                    About
                </a>
            </li>
        </ul>
        <p aria-level="2" class="caption" role="heading">
 <span class="caption-text">
  News
 </span>
</p>
<ul class="current nav bd-sidenav">
 <li class="toctree-l1 current active">
  <a class="current reference internal" href="#">
   2022 (lst)
  </a>
 </li>
</ul>
<p aria-level="2" class="caption" role="heading">
 <span class="caption-text">
  TOPIC
 </span>
</p>
<ul class="nav bd-sidenav">
 <li class="toctree-l1 has-children">
  <a class="reference internal" href="../ch002covid19/ch002_covid19.html">
   COVID-19
  </a>
  <input class="toctree-checkbox" id="toctree-checkbox-1" name="toctree-checkbox-1" type="checkbox"/>
  <label for="toctree-checkbox-1">
   <i class="fas fa-chevron-down">
   </i>
  </label>
  <ul>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch002_y2020_statistical.html">
     Statistical Considerations (2020)
    </a>
   </li>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch002_y2020_dev_trt_prevention.html">
     Dev for Treatment or Prevention (2020)
    </a>
   </li>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch102_y2020_dev_vaccine.html">
     Vaccine Development (2020)
    </a>
   </li>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch102_y2022_eua_vaccine.html">
     EUA Vaccine (2022)
    </a>
   </li>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch002_y2021_mAb.html">
     mAb Targeting SARS-CoV-2 (2021)
    </a>
   </li>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch002covid19/ch002_y2021_master_protocol.html">
     Master Protocols (2021)
    </a>
   </li>
  </ul>
 </li>
 <li class="toctree-l1 has-children">
  <a class="reference internal" href="../ch003vaccine/ch003_vaccine.html">
   Vaccine
  </a>
  <input class="toctree-checkbox" id="toctree-checkbox-2" name="toctree-checkbox-2" type="checkbox"/>
  <label for="toctree-checkbox-2">
   <i class="fas fa-chevron-down">
   </i>
  </label>
  <ul>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch003vaccine/ch003_y2007_pandemic_influenza.html">
     Pandemic Influenza (2007)
    </a>
   </li>
  </ul>
 </li>
 <li class="toctree-l1 has-children">
  <a class="reference internal" href="../ch010ich/ch010_ich.html">
   ICH
  </a>
  <input class="toctree-checkbox" id="toctree-checkbox-3" name="toctree-checkbox-3" type="checkbox"/>
  <label for="toctree-checkbox-3">
   <i class="fas fa-chevron-down">
   </i>
  </label>
  <ul>
   <li class="toctree-l2">
    <a class="reference internal" href="../ch010ich/ch010_ich_m10_y2019_bioanalytical_validation.html">
     M10 (2006) BIOANALYTICAL VALIDATION
    </a>
   </li>
  </ul>
 </li>
</ul>
<p aria-level="2" class="caption" role="heading">
 <span class="caption-text">
  EMA
 </span>
</p>
<ul class="nav bd-sidenav">
 <li class="toctree-l1 has-children">
  <a class="reference internal" href="../ech001vaccine/che000_ema.html">
   EMA Scientific Guidelines
  </a>
  <input class="toctree-checkbox" id="toctree-checkbox-4" name="toctree-checkbox-4" type="checkbox"/>
  <label for="toctree-checkbox-4">
   <i class="fas fa-chevron-down">
   </i>
  </label>
  <ul>
   <li class="toctree-l2">
    <a class="reference internal" href="../ech001vaccine/che001_y2017_immuno_protein.html">
     Immunogenicity assessment (2017)
    </a>
   </li>
  </ul>
 </li>
</ul>

    </div>
</nav></div>
        <div class="bd-sidebar__bottom">
             <!-- To handle the deprecated key -->
            
        </div>
    </div>
    <div id="rtd-footer-container"></div>
</div>


          


          
<!-- A tiny helper pixel to detect if we've scrolled -->
<div class="sbt-scroll-pixel-helper"></div>
<!-- Main content -->
<div class="col py-0 content-container">
    
    <div class="header-article row sticky-top noprint">
        



<div class="col py-1 d-flex header-article-main">
    <div class="header-article__left">
        
        <label for="__navigation"
  class="headerbtn"
  data-toggle="tooltip"
data-placement="right"
title="Toggle navigation"
>
  

<span class="headerbtn__icon-container">
  <i class="fas fa-bars"></i>
  </span>

</label>

        
    </div>
    <div class="header-article__right">
<div class="menu-dropdown menu-dropdown-launch-buttons">
  <button class="headerbtn menu-dropdown__trigger"
      aria-label="Launch interactive content">
      <i class="fas fa-rocket"></i>
  </button>
  <div class="menu-dropdown__content">
    <ul>
      <li>
        <a href="https://mybinder.org/v2/gh/executablebooks/jupyter-book/master?urlpath=tree/ch000news/news2022.ipynb"
   class="headerbtn"
   data-toggle="tooltip"
data-placement="left"
title="Launch on Binder"
>
  

<span class="headerbtn__icon-container">
  
    <img src="../_static/images/logo_binder.svg">
  </span>
<span class="headerbtn__text-container">Binder</span>
</a>

      </li>
      
    </ul>
  </div>
</div>

<button onclick="toggleFullScreen()"
  class="headerbtn"
  data-toggle="tooltip"
data-placement="bottom"
title="Fullscreen mode"
>
  

<span class="headerbtn__icon-container">
  <i class="fas fa-expand"></i>
  </span>

</button>

<div class="menu-dropdown menu-dropdown-download-buttons">
  <button class="headerbtn menu-dropdown__trigger"
      aria-label="Download this page">
      <i class="fas fa-download"></i>
  </button>
  <div class="menu-dropdown__content">
    <ul>
      <li>
        <a href="../_sources/ch000news/news2022.ipynb"
   class="headerbtn"
   data-toggle="tooltip"
data-placement="left"
title="Download source file"
>
  

<span class="headerbtn__icon-container">
  <i class="fas fa-file"></i>
  </span>
<span class="headerbtn__text-container">.ipynb</span>
</a>

      </li>
      
      <li>
        
<button onclick="printPdf(this)"
  class="headerbtn"
  data-toggle="tooltip"
data-placement="left"
title="Print to PDF"
>
  

<span class="headerbtn__icon-container">
  <i class="fas fa-file-pdf"></i>
  </span>
<span class="headerbtn__text-container">.pdf</span>
</button>

      </li>
      
    </ul>
  </div>
</div>

    </div>
</div>

<!-- Table of contents -->
<div class="col-md-3 bd-toc show noprint">
</div>
    </div>
    <div class="article row">
        <div class="col pl-md-3 pl-lg-5 content-container">
            <!-- Table of contents that is only displayed when printing the page -->
            <div id="jb-print-docs-body" class="onlyprint">
                <h1>2022 (lst)</h1>
                <!-- Table of contents -->
                <div id="print-main-content">
                    <div id="jb-print-toc">
                        
                    </div>
                </div>
            </div>
            <main id="main-content" role="main">
                
              <div>
                
  <section class="tex2jax_ignore mathjax_ignore" id="lst">
<h1>2022 (lst)<a class="headerlink" href="#lst" title="Permalink to this headline">#</a></h1>
<div class="cell tag_hide-input docutils container">
<div class="cell_input docutils container">
<div class="highlight-ipython3 notranslate"><div class="highlight"><pre><span></span><span class="kn">import</span> <span class="nn">pandas</span> <span class="k">as</span> <span class="nn">pd</span>
<span class="kn">from</span> <span class="nn">IPython.display</span> <span class="kn">import</span> <span class="n">Markdown</span> <span class="k">as</span> <span class="n">md</span>
<span class="n">pd</span><span class="o">.</span><span class="n">set_option</span><span class="p">(</span><span class="s1">&#39;display.max_rows&#39;</span><span class="p">,</span> <span class="mi">200</span><span class="p">,</span> <span class="s1">&#39;display.max_colwidth&#39;</span><span class="p">,</span> <span class="kc">None</span><span class="p">)</span>

<span class="k">if</span><span class="p">(</span><span class="kc">True</span><span class="p">):</span>
    <span class="kn">import</span> <span class="nn">sys</span>
    <span class="n">sys</span><span class="o">.</span><span class="n">path</span><span class="o">.</span><span class="n">insert</span><span class="p">(</span><span class="mi">0</span><span class="p">,</span> <span class="s1">&#39;..&#39;</span><span class="p">)</span>
    <span class="kn">import</span> <span class="nn">myutil.pdf2txt</span>
    <span class="n">myutil</span><span class="o">.</span><span class="n">pdf2txt</span><span class="o">.</span><span class="n">fxlsx2csv</span><span class="p">(</span><span class="s2">&quot;../suppfiles/lstcurrent&quot;</span><span class="p">)</span>
<span class="n">df</span><span class="o">=</span><span class="n">pd</span><span class="o">.</span><span class="n">read_csv</span><span class="p">(</span><span class="s2">&quot;../suppfiles/lstcurrent.csv&quot;</span><span class="p">)</span>
<span class="n">lst2</span><span class="o">=</span><span class="n">df</span><span class="o">.</span><span class="n">drop</span><span class="p">([</span><span class="s1">&#39;Unnamed: 0&#39;</span><span class="p">,</span><span class="s1">&#39;Open for Comment&#39;</span><span class="p">],</span> <span class="n">axis</span><span class="o">=</span><span class="mi">1</span><span class="p">)</span><span class="o">.</span><span class="n">set_index</span><span class="p">([</span><span class="s1">&#39;Issue Date&#39;</span><span class="p">])</span><span class="o">.</span><span class="n">filter</span><span class="p">(</span><span class="n">regex</span><span class="o">=</span><span class="s1">&#39;2022&#39;</span><span class="p">,</span><span class="n">axis</span><span class="o">=</span><span class="mi">0</span><span class="p">)</span><span class="o">.</span><span class="n">reset_index</span><span class="p">()</span><span class="o">.</span><span class="n">drop</span><span class="p">([</span><span class="s1">&#39;Docket Number&#39;</span><span class="p">,</span> <span class="s1">&#39;Issue Date&#39;</span><span class="p">,</span><span class="s1">&#39;Topic&#39;</span><span class="p">],</span> <span class="n">axis</span><span class="o">=</span><span class="mi">1</span><span class="p">)</span><span class="o">.</span><span class="n">set_index</span><span class="p">([</span><span class="s1">&#39;Issue Date0&#39;</span><span class="p">,</span><span class="s1">&#39;Guidance Status&#39;</span><span class="p">])</span>

<span class="n">md</span><span class="p">(</span><span class="s2">&quot;There are &quot;</span><span class="o">+</span><span class="nb">str</span><span class="p">(</span><span class="nb">len</span><span class="p">(</span><span class="n">lst2</span><span class="p">))</span><span class="o">+</span><span class="s2">&quot; documents issued during the year of 2022. Below is a list of those documents.&quot;</span><span class="p">)</span>
</pre></div>
</div>
</div>
<div class="cell_output docutils container">
<p>There are 148 documents issued during the year of 2022. Below is a list of those documents.</p>
</div>
</div>
<div class="cell tag_hide-input docutils container">
<div class="cell_input docutils container">
<div class="highlight-ipython3 notranslate"><div class="highlight"><pre><span></span><span class="n">lst2</span>
</pre></div>
</div>
</div>
<div class="cell_output docutils container">
<div class="output text_html"><div>
<style scoped>
    .dataframe tbody tr th:only-of-type {
        vertical-align: middle;
    }

    .dataframe tbody tr th {
        vertical-align: top;
    }

    .dataframe thead th {
        text-align: right;
    }
</style>
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th></th>
      <th>Summary</th>
      <th>FDA Organization</th>
    </tr>
    <tr>
      <th>Issue Date0</th>
      <th>Guidance Status</th>
      <th></th>
      <th></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th rowspan="2" valign="top">2022-09-07</th>
      <th>Draft</th>
      <td>General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="5" valign="top">2022-08-26</th>
      <th>Draft</th>
      <td>E11A Pediatric Extrapolation</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>M12 Drug Interaction Studies</td>
      <td>(CDER) ,Office of Regulatory Policy</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Q14 Analytical Procedure Development</td>
      <td>(CDER) ,Office of Regulatory Policy</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Q2(R2) Validation of Analytical Procedures</td>
      <td>(CDER) ,Office of Regulatory Policy</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-08-23</th>
      <th>Final</th>
      <td>Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies</td>
      <td>(CTP)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Charging for Investigational Drugs Under an IND: Questions and Answers</td>
      <td>(CDER) Office of the Commissioner,Office of Clinical Policy and Programs</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-08-17</th>
      <th>Final</th>
      <td>Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>2022-08-15</th>
      <th>Final</th>
      <td>FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="9" valign="top">2022-08-12</th>
      <th>Draft</th>
      <td>CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-08-10</th>
      <th>Final</th>
      <td>CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>2022-08-05</th>
      <th>Final</th>
      <td>Bioresearch Monitoring Technical Conformance Guide</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-08-02</th>
      <th>Draft</th>
      <td>Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-08-01</th>
      <th>Final</th>
      <td>Guidance for Industry: Policy Regarding N-acetyl-L-cysteine</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>2022-07-29</th>
      <th>Final</th>
      <td>Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry</td>
      <td>(CVM) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th>2022-07-28</th>
      <th>Draft</th>
      <td>Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-07-27</th>
      <th>Final</th>
      <td>General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th>2022-07-25</th>
      <th>Final</th>
      <td>Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CBER) (CDRH)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-07-22</th>
      <th>Final</th>
      <td>Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry</td>
      <td>(CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry</td>
      <td>(ORA)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Real-Time Oncology Review (RTOR) : Draft Guidance for Industry</td>
      <td>(OCE)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-07-21</th>
      <th>Draft</th>
      <td>Evaluation of Therapeutic Equivalence</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”</td>
      <td>(CBER) (CDER)</td>
    </tr>
    <tr>
      <th>2022-07-18</th>
      <th>Draft</th>
      <td>CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>2022-07-15</th>
      <th>Final</th>
      <td>Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>2022-07-08</th>
      <th>Final</th>
      <td>CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>2022-07-06</th>
      <th>Draft</th>
      <td>DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-07-05</th>
      <th>Draft</th>
      <td>Identifying Trading Partners Under the Drug Supply Chain Security Act</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-07-01</th>
      <th>Final</th>
      <td>CVM GFI #108 Registering with CVM’s Electronic Submission System</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>2022-06-29</th>
      <th>Draft</th>
      <td>Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-06-28</th>
      <th>Final</th>
      <td>Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-06-27</th>
      <th>Final</th>
      <td>Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-06-24</th>
      <th>Final</th>
      <td>Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Considerations for Rescinding Breakthrough Therapy Designation</td>
      <td>(CDER) (CBER) (OCE)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry</td>
      <td>(CDER) (CBER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-06-21</th>
      <th>Final</th>
      <td>FDA Oversight of Food Covered by Systems Recognition Arrangements</td>
      <td>(ORA)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>2022-06-16</th>
      <th>Final</th>
      <td>Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>2022-06-15</th>
      <th>Draft</th>
      <td>Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies: Draft Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>2022-06-14</th>
      <th>Draft</th>
      <td>Q9(R1) Quality Risk Management</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-06-06</th>
      <th>Final</th>
      <td>Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th>2022-06-01</th>
      <th>Final</th>
      <td>Guidance for Industry: Fish and Fishery Products Hazards and Controls</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>2022-05-27</th>
      <th>Final</th>
      <td>Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-05-25</th>
      <th>Final</th>
      <td>Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide</td>
      <td>(ORA)</td>
    </tr>
    <tr>
      <th>2022-05-24</th>
      <th>Draft</th>
      <td>Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1)</td>
      <td>(CDER) ,Office of New Drugs</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-05-23</th>
      <th>Final</th>
      <td>Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy: Draft Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements: Draft Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-05-19</th>
      <th>Draft</th>
      <td>Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification</td>
      <td>(CFSAN) ,Office of Dietary Supplement Programs</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Risk Management Plans to Mitigate the Potential for Drug Shortages</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-05-18</th>
      <th>Final</th>
      <td>Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-05-17</th>
      <th>Final</th>
      <td>Assessing User Fees Under the Generic Drug User Fee Amendments of 2017</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-05-16</th>
      <th>Final</th>
      <td>Guidance for Industry: Infant Formula Enforcement Discretion Policy</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-05-13</th>
      <th>Final</th>
      <td>Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-05-10</th>
      <th>Final</th>
      <td>CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>2022-05-09</th>
      <th>Draft</th>
      <td>Benefit-Risk Considerations for Product Quality Assessments</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-05-06</th>
      <th>Final</th>
      <td>Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-05-04</th>
      <th>Draft</th>
      <td>Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (Revised):  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CBER) (CDRH)</td>
    </tr>
    <tr>
      <th>2022-05-02</th>
      <th>Draft</th>
      <td>Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability</td>
      <td>(OCE)</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-04-29</th>
      <th>Final</th>
      <td>E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry</td>
      <td>(CDER) (OCE) (CBER)</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-04-28</th>
      <th>Draft</th>
      <td>Crohn’s Disease:  Developing Drugs for Treatment</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Draft Guidance for Industry: The Accredited Third-Party Certification Program: Questions and Answers</td>
      <td>(CVM) (ORA) (CFSAN)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Ulcerative Colitis:  Developing Drugs for Treatment</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-04-27</th>
      <th>Final</th>
      <td>Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation</td>
      <td>(CVM) (CFSAN)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Providing Submissions in Electronic Format — Postmarketing Safety Reports</td>
      <td>(CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Draft Guidance for Industry: Action Levels for Lead in Juice</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-04-21</th>
      <th>Final</th>
      <td>Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th>2022-04-20</th>
      <th>Draft</th>
      <td>CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>2022-04-18</th>
      <th>Draft</th>
      <td>Draft Guidance for FDA Staff and Stakeholders: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-04-15</th>
      <th>Final</th>
      <td>Bioavailability Studies Submitted in NDAs or INDs – General Considerations</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet</td>
      <td>(CDER) ,Office of New Drugs(CBER)</td>
    </tr>
    <tr>
      <th>2022-04-14</th>
      <th>Draft</th>
      <td>Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-04-13</th>
      <th>Final</th>
      <td>Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Diversity Plans to Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials; Draft Guidance for Industry; Availability: Draft Guidance for Industry</td>
      <td>(OCE) (CDER) (CBER) (CDRH) Office of the Commissioner,Office of Minority Health and Health Equity</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-04-11</th>
      <th>Final</th>
      <td>Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs</td>
      <td>(CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-04-08</th>
      <th>Final</th>
      <td>E8(R1) General Considerations for Clinical Studies</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-04-07</th>
      <th>Final</th>
      <td>Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers: Draft Guidance for Industry</td>
      <td>(CDER) (CBER) (CDRH) (CFSAN) (CTP) (ORA) (CVM)</td>
    </tr>
    <tr>
      <th>2022-04-06</th>
      <th>Draft</th>
      <td>M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-03-31</th>
      <th>Final</th>
      <td>Emergency Use Authorization for Vaccines to Prevent COVID-19:  Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-03-22</th>
      <th>Final</th>
      <td>An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry</td>
      <td>(CBER) (CDRH) (CDER)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-03-15</th>
      <th>Draft</th>
      <td>Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Human Gene Therapy Products Incorporating Human Genome Editing</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>2022-03-11</th>
      <th>Final</th>
      <td>Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions</td>
      <td>(CFSAN) (CVM) (ORA)</td>
    </tr>
    <tr>
      <th>2022-03-09</th>
      <th>Draft</th>
      <td>Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs: Draft Guidance for Industry</td>
      <td>(CDER) ,Office of Regulatory Policy</td>
    </tr>
    <tr>
      <th>2022-03-04</th>
      <th>Final</th>
      <td>Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff</td>
      <td>(CVM) (ORA) (CFSAN) (CBER) (CDRH) (CDER) (CTP)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-03-02</th>
      <th>Draft</th>
      <td>CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Physician Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff</td>
      <td>(CDRH)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-03-01</th>
      <th>Final</th>
      <td>Guidance for Industry: FDA's Voluntary Qualified Importer Program</td>
      <td>(CVM) (ORA) (CFSAN)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry</td>
      <td>(CDER) (CBER) (OCE)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry</td>
      <td>Office of the Commissioner(CDER)</td>
    </tr>
    <tr>
      <th>2022-02-25</th>
      <th>Final</th>
      <td>Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-02-24</th>
      <th>Final</th>
      <td>Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th rowspan="2" valign="top">2022-02-09</th>
      <th>Final</th>
      <td>Guidance for Industry: Questions and Answers Regarding Channels of Trade Policy for Human Food Commodities with Chlorpyrifos Residues</td>
      <td>(CFSAN)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-02-08</th>
      <th>Final</th>
      <td>COVID-19 Public Health Emergency Policy on COVID-19-Related Sanitation Tunnels:  Guidance for Industry and Investigators</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>2022-02-07</th>
      <th>Draft</th>
      <td>Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry: Draft Guidance for Industry</td>
      <td>(CDER) (CBER)</td>
    </tr>
    <tr>
      <th>2022-02-04</th>
      <th>Final</th>
      <td>Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic:  Guidance for Industry</td>
      <td>(OCE) (CBER) (CDER)</td>
    </tr>
    <tr>
      <th rowspan="4" valign="top">2022-02-03</th>
      <th>Final</th>
      <td>Drug Product Tracing: The Effect of Section 585 of the FD&amp;C Act</td>
      <td>(CDER) (CBER) (ORA)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Population Pharmacokinetics:  Guidance for Industry</td>
      <td>(CDER) (CBER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry</td>
      <td>(CDER) (CBER)</td>
    </tr>
    <tr>
      <th>2022-02-01</th>
      <th>Draft</th>
      <td>Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs</td>
      <td>(CDER) ,Office of New Drugs</td>
    </tr>
    <tr>
      <th rowspan="5" valign="top">2022-01-26</th>
      <th>Final</th>
      <td>Good ANDA Submission Practices Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry</td>
      <td>(CDER) (CBER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff</td>
      <td>(CBER) (CDRH) (CDER) Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th>2022-01-25</th>
      <th>Draft</th>
      <td>Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry: Draft Guidance for Industry</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th rowspan="3" valign="top">2022-01-21</th>
      <th>Final</th>
      <td>CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI</td>
      <td>(CVM)</td>
    </tr>
    <tr>
      <th>Final</th>
      <td>Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document</td>
      <td>(CDER)</td>
    </tr>
    <tr>
      <th>Draft</th>
      <td>Digital Health Technologies for Remote Data Acquisition in Clinical Investigations: Draft Guidance for Industry, Investigators, and Other Stakeholders</td>
      <td>(OCE) (CBER) (CDRH) (CDER)</td>
    </tr>
    <tr>
      <th>2022-01-11</th>
      <th>Draft</th>
      <td>Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&amp;C Act: Draft Guidance for Industry and Food and Drug Administration Staff</td>
      <td>(CDRH) (CBER)</td>
    </tr>
    <tr>
      <th>2022-01-07</th>
      <th>Final</th>
      <td>Investigational COVID-19 Convalescent Plasma:  Guidance for Industry</td>
      <td>(CBER)</td>
    </tr>
    <tr>
      <th>2022-01-01</th>
      <th>Draft</th>
      <td>Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry</td>
      <td>(CDER) (CVM) (ORA) (CBER) (CFSAN)</td>
    </tr>
  </tbody>
</table>
</div></div></div>
</div>
</section>

    <script type="text/x-thebe-config">
    {
        requestKernel: true,
        binderOptions: {
            repo: "binder-examples/jupyter-stacks-datascience",
            ref: "master",
        },
        codeMirrorConfig: {
            theme: "abcdef",
            mode: "nbenv"
        },
        kernelOptions: {
            kernelName: "nbenv",
            path: "./ch000news"
        },
        predefinedOutput: true
    }
    </script>
    <script>kernelName = 'nbenv'</script>

              </div>
              
            </main>
            <footer class="footer-article noprint">
                
    <!-- Previous / next buttons -->
<div class='prev-next-area'>
    <a class='left-prev' id="prev-link" href="../index.html" title="previous page">
        <i class="fas fa-angle-left"></i>
        <div class="prev-next-info">
            <p class="prev-next-subtitle">previous</p>
            <p class="prev-next-title">About</p>
        </div>
    </a>
    <a class='right-next' id="next-link" href="../ch002covid19/ch002_covid19.html" title="next page">
    <div class="prev-next-info">
        <p class="prev-next-subtitle">next</p>
        <p class="prev-next-title">COVID-19</p>
    </div>
    <i class="fas fa-angle-right"></i>
    </a>
</div>
            </footer>
        </div>
    </div>
    <div class="footer-content row">
        <footer class="col footer"><p>
  
    By Y. Hsu<br/>
  
      &copy; Copyright 2022.<br/>
    <div class="extra_footer">
      <a rel="license" href="http://creativecommons.org/licenses/by-nc/4.0/"><img alt="Creative Commons License" style="border-width:0" src="https://i.creativecommons.org/l/by-nc/4.0/88x31.png"></a> <BR> This work is licensed under a <a rel="license" href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License</a> <BR><BR> Powered by <a href="https://jupyterbook.org">Jupyter Book</a>
    </div>
</p>
        </footer>
    </div>
    
</div>


      </div>
    </div>
  
  <!-- Scripts loaded after <body> so the DOM is not blocked -->
  <script src="../_static/scripts/pydata-sphinx-theme.js?digest=1999514e3f237ded88cf"></script>


  </body>
</html>